Zamenix Robot Hits 200 Surgeries in 4 Months
AI-powered kidney stone robot achieves rapid clinical adoption in South Korea
Recap
Source: 로봇신문, report of Sept. 29, 2026
According to the report, Roen Surgical announced that its AI-based kidney stone surgery robot, Zamenix, has surpassed 200 cumulative surgical cases. This milestone was achieved just four months after the device received approval for clinical use as an innovative medical technology in South Korea.
The company highlights data from a randomized controlled trial (RCT) presented at a recent robotic ureteroscopy society meeting. These results demonstrate the robot's safety and efficacy compared to standard retrograde intrarenal surgery (RIRS). Notably, the analysis of the 200 patients indicates successful single-session treatment for high-difficulty stones ranging from 3 to 4 cm, a category previously often treated with percutaneous nephrolithotomy (PCNL). Roen Surgical states that no severe complications have been reported, with patients showing recovery trajectories that allow discharge the day after surgery.
The report also notes operational benefits for hospitals. The ergonomic master console is said to reduce surgeon fatigue during long procedures, enabling multiple surgeries per day. Additionally, the integration of a suction-assisted device (FANS) has contributed to better visualization and stone clearance, reducing overall operation time. Currently, the robot is deployed in 23 hospitals in South Korea and one institution overseas.
Context
Zamenix is described as the first AI-based kidney stone surgery robot to receive US FDA 510(k) clearance. It features proprietary AI control technologies, including respiratory compensation, stone size guidance, and autonomous navigation. In the broader surgical robotics market, kidney stone treatment has traditionally relied on minimally invasive techniques like RIRS or more invasive PCNL for larger stones. The introduction of a robotic system that can handle large stones without percutaneous access represents a significant shift in urological intervention options, aiming to reduce patient recovery time and hospital resource utilization.
Robot's take
The rapid adoption of 200 cases in four months suggests strong clinical acceptance, particularly given the positive RCT data. The ability to treat 3-4 cm stones in a single session without PCNL is a compelling clinical advantage that could change standard of care guidelines. However, long-term data on stone recurrence rates and durability of the single-session success rate will be crucial for validating these early claims. The ergonomic benefits for surgeons are also a significant factor in hospital adoption, as reducing physical strain can improve throughput and surgeon well-being. Watch for further peer-reviewed publications and multi-center studies to confirm these initial results.
corrections · reports
Found a mistake? The AI (Litmus) compares the article with its source, decides whether to fix it and tells you why. When the AI finds that a fix is needed, it drafts one, and the fix is applied after a human editor approves it. Every fix is listed here and in the changelog.
Sources
This story was written by Robopedia based on the sources below.
Learn more